Search Results



Your search for Matthew Stenger matches 3132 pages

Showing 1 - 50


Addition of Metronomic Chemotherapy to Dual Anti-HER2 Treatment in Older Patients With Metastatic Breast Cancer

In the phase II EORTC 75111-10114 trial reported in The Lancet Oncology, Wildiers et al found that the addition of metronomic oral cyclophosphamide to pertuzumab (Perjeta) and trastuzumab (Herceptin) improved progression-free survival in elderly or frail women with HER2-positive metastatic breast...

Dose Rounding of Anticancer Agents: Hematology/Oncology Pharmacy Association Position Statement

As reported in the Journal of Oncology Practice by Fahrenbruch et al, the Hematology/Oncology Pharmacy Association (HOPA) has issued a position statement on dose rounding of biologic and cytotoxic anticancer agents. To formulate the position statement, the HOPA standards committee organized a work ...

Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis

In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....

Long-Term Outcomes With PD-L1 Inhibition in Metastatic Urothelial Cancer

As reported by Petrylak et al in JAMA Oncology, long-term follow-up of patients in a phase I study expansion cohort indicated enduring clinical benefit and maintained tolerability of atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma.  Study Details The study involved...

Chromatin Organization Marker and Cancer-Specific Survival

In a study reported in The Lancet Oncology, Kleppe et al found that a novel marker for chromatin organization in tumor cell nuclei was associated with outcome in a variety of cancer types. Study Details In the study, machine learning algorithms analyzed chromatin organization in 461,000 images of ...

Pomalidomide and Low-Dose Dexamethasone in Patients With Multiple Myeloma and Renal Impairment

In a European phase II trial reported in the Journal of Clinical Oncology, Dimopoulos et al found that pomalidomide (Pomalyst) plus low-dose dexamethasone produced responses in patients with relapsed or refractory multiple myeloma and renal impairment. Study Details In the study, 81 patients with ...

Association of MHC Class II and PD-L1 Expression With Outcome in Classical Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology, Roemer et al found that programmed death cell ligand 1 (PD-L1) expression and major histocompatibility complex (MHC) class II positivity on Hodgkin Reed-Sternberg (HRS) cells may predict favorable outcome with programmed cell death protein 1 (PD-1)...

Monoclonal Antibody Treatment in Newly Diagnosed Pediatric High-Grade Glioma

In a phase II study reported in the Journal of Clinical Oncology, Grill et al found that the addition of bevacizumab (Avastin) to radiotherapy plus temozolomide (RT + TMZ) did not improve event-free survival in pediatric patients with newly diagnosed high-grade glioma. Study Details In the...

ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer

As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) updated guideline on molecular...

First-Line Lenvatinib vs Sorafenib in Unresectable Hepatocellular Carcinoma

In a phase III noninferiority trial reported in The Lancet, Kudo et al found that first-line lenvatinib was noninferior to sorafenib in overall survival of patients with unresectable hepatocellular carcinoma. Study Details In the open-label trial, 954 patients from 154 sites in 20 countries in...

Combination Immunotherapy in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

As reported in the Journal of Clinical Oncology by Overman et al, findings in the nivolumab (Opdivo) plus ipilimumab (Yervoy) cohort of the CheckMate-142 study indicate a high response rate and durable responses with the combination in previously treated patients with DNA mismatch...

Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...

Neoadjuvant Trastuzumab Biosimilar vs Trastuzumab in HER2-Positive Early Breast Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Pivot et al found equivalence of the trastuzumab biosimilar SB3 and the reference trastuzumab (Herceptin) in producing breast pathologic complete response in the neoadjuvant treatment of patients with HER2-positive early breast...

ALK Variant, Resistance, and Clinical Outcomes in ALK-Positive NSCLC

In a study reported in the Journal of Clinical Oncology, Lin et al found that specific ALK variants may be associated with the development of resistance mutations to ALK tyrosine kinase inhibitors (TKIs) in ALK-positive non–small cell lung cancer (NSCLC). Study Details The study involved...

METEOR Trial Follow-up: Quality of Life in Metastatic RCC

In a study reported in the Journal of Clinical Oncology, Cella et al found little difference in quality-of-life (QOL) outcomes between the cabozantinib (Cabometyx) and everolimus (Afinitor) groups in the phase III METEOR trial. The study investigated these treatments in patients with metastatic...

Selective Inhibition of Nuclear Export in Heavily Pretreated Relapsed or Refractory Multiple Myeloma

In a phase II trial reported in the Journal of Clinical Oncology, Vogl et al found that the investigational oral selective exportin 1 (XPO1) inhibitor selinexor combined with dexamethasone produced responses in patients with heavily pretreated relapsed or refractory multiple myeloma. ...

Synchronous Distant and Locoregional Recurrence in Stage II and III Breast Cancer

In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Neuman et al found that synchronous distant recurrence was identified in 27% of women with stage II or III breast cancer experiencing locoregional recurrence. Study Details The study—an American...

breast cancer

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

AS REPORTED BY Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying...

bladder cancer

Avelumab Active in Advanced Urothelial Carcinoma After Platinum Failure

AS REPORTED in The Lancet Oncology by Manish R. Patel, MD, of Florida Cancer Specialists/Sarah Cannon Research Institute, and colleagues, the anti–programmed cell death ligand 1 (PD-L1) antibody avelumab (Bavencio) produced durable responses in patients with locally advanced or metastatic...

Nonsteroidal Antiandrogen Treatment in Androgen Receptor–Expressing Triple-Negative Breast Cancer

A phase II study reported in the Journal of Clinical Oncology by Traina et al showed activity of the androgen receptor inhibitor enzalutamide (Xtandi) in triple-negative breast cancer expressing the androgen receptor (AR). Study Details The study involved 118 patients from 45 sites in seven...

Prosigna Score and 10-Year Distant Recurrence in Women Receiving Endocrine Therapy for Early Breast Cancer

In a Danish study reported in the Journal of Clinical Oncology, Lænkholm and colleagues found that the PAM50-based Prosigna risk of recurrence score could identify lower risk of 10-year distant recurrence in subgroups of postmenopausal women who received 5 years of endocrine therapy alone for ...

Pembrolizumab Active in Thymic Carcinoma

In a single-center phase II study reported in The Lancet Oncology, Giaccone et al found that pembrolizumab (Keytruda) produced durable responses in patients with recurrent thymic carcinoma. Study Details In the study, 40 evaluable patients with advanced disease progressing after at least one line ...

Long-Term Follow-up in Follicular Lymphoma: SWOG Phase III Trial Reports Outcomes

As reported in the Journal of Clinical Oncology by Shadman et al, long-term follow-up of patients with previously untreated advanced-stage follicular lymphoma in the phase III SWOG-S0016 trial has shown continued good outcomes with both R-CHOP (rituximab [Rituxan] plus cyclophosphamide,...

Prexasertib in Pretreated BRCA Wild-Type High-Grade Serous Ovarian Cancer

In a phase II study reported in The Lancet Oncology by Lee et al, the investigational cell-cycle checkpoint kinase 1 and 2 inhibitor prexasertib produced responses in women with recurrent BRCA wild-type high-grade serous ovarian cancer. In the study, 28 women with measureable disease enrolled...

CONCORD-3: Global Surveillance of Cancer Survival Trends, 2000–2014

In an article in The Lancet, Allemani et al reported findings from the CONCORD program for global surveillance of cancer survival trends updated through 2014 (CONCORD-3).   Study Details CONCORD-3 includes data on 37.5 million patients diagnosed with cancer between 2000 and 2014 from...

ASCO Clinical Practice Guideline: Treatment of Malignant Pleural Mesothelioma

As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on treatment of malignant pleural mesothelioma. The guideline was informed by a systematic literature search and expert panel review ...

Nab-Paclitaxel vs Paclitaxel in Neoadjuvant Treatment of HER2-Negative Breast Cancer

In a European phase III trial (ETNA) reported in JAMA Oncology, Gianni et al found no significant difference in pathologic complete response rate with nab-paclitaxel (Abraxane) vs paclitaxel followed by an anthracycline regimen in neoadjuvant treatment for HER2-negative breast cancer. Study...

Long-Term Results of PET-Adapted Therapy for Advanced Hodgkin Lymphoma

As reported by Gallamini et al in the Journal of Clinical Oncology, the Italian GITIL/FIL HD 0607 trial has shown good long-term outcomes with the switch from ABVD (doxorubicin, vinblastine, vincristine, and dacarbazine) to escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide,...

Nivolumab With or Without Ipilimumab in Advanced Sarcoma

In the phase II Alliance A091401 trial reported in The Lancet Oncology, D’Angelo et al found evidence of activity of nivolumab plus ipilimumab in advanced sarcoma. Study Details The study comprised two noncomparative randomized phase II trials in which a total of 85 eligible patients...

Combined Aerobic-Resistance Exercise Intervention in Overweight/Obese Survivors of Breast Cancer

In a study reported in the Journal of Clinical Oncology, Dieli-Conwright et al found that an aerobic and resistance intervention reduced metabolic syndrome factors and sarcopenic obesity among sedentary, overweight, or obese women with breast cancer. Study Details In the study, 100 women from...

solid tumors

Individualized Adaptive Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors

In a single-center phase II study reported in JAMA Oncology, Feng and colleagues found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control with low complication rates in patients with liver tumors and preexisting liver dysfunction. Theodore S....

solid tumors

Health-Related Quality of Life in Everolimus-Treated Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel and colleagues, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...

cns cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported in The Lancet...

hematologic malignancies
multiple myeloma

Daratumumab in Previously Treated Multiple Myeloma

  On June 16, 2017, daratumumab -(Darzalex) was approved for use in combination with pomalidomide (Pomalyst) and dexamethasone for treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor.1,2 Supporting...

solid tumors

Pembrolizumab in MSI-H or dMMR Solid Tumors: ‘First Tissue/Site-Agnostic’ Approval by FDA

  On May 23, 2017, pembrolizumab (Keytruda) was granted accelerated approval for treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors progressing following prior treatment and who have no...

Posttreatment Mortality With Stereotactic Body Radiotherapy vs Surgery in NSCLC

In a study reported in the Journal of Clinical Oncology, Stokes and colleagues found lower posttreatment mortality rates with stereotactic body radiotherapy (SBRT) vs surgery in early-stage non–small cell lung cancer (NSCLC), with the difference in rates increasing as a function of age....

hematologic malignancies
leukemia

Enasidenib in IDH2-Mutant Relapsed or Refractory Acute Myeloid Leukemia

  On August 1, 2017, the IDH2 inhibitor enasidenib (Idhifa) was granted regular approval for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by a U.S. Food and Drug Administration (FDA)-approved...

hematologic malignancies
leukemia

Blinatumomab in Relapsed or Refractory B-Cell Precursor ALL

On July 11, 2017, blinatumomab (Blincyto) was approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.1,2 Blinatumomab received accelerated approval in December 2014 for the treatment of Philadelphia chromosome (Ph)-negative...

Potential Effect of Excess Body Weight on Detection of Cervical Precancer

In a study reported in the Journal of Clinical Oncology, Clarke et al found that increasing body mass index (BMI) was associated with lower rates of cervical precancer diagnosis and higher rates of cervical cancer diagnosis. The investigators had hypothesized that increased body mass could decrease ...

Addition of Antibody-Drug Conjugate to Low-Intensity Chemotherapy in Older Patients With ALL

In a single-center phase II study reported in The Lancet Oncology, Kantarjian et al found that the addition of inotuzumab ozogamicin (Besponsa) to low-intensity chemotherapy produced promising outcomes in older patients with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic ...

breast cancer
survivorship

Effects of Group Psychosocial Intervention on Body Image and Quality of Life in Breast Cancer Survivors

In a study reported in the Journal of Clinical Oncology, Esplen et al found that a group psychosocial intervention was effective in improving body image concerns and breast cancer–related quality of life among breast cancer survivors. Study Details In the study, 194 breast cancer survivors...

Is There a Benefit of Maintenance Bevacizumab During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer?

As reported by Aparicio et al in the Journal of Clinical Oncology, a French phase III trial (PRODIGE 9) showed no benefit of maintenance bevacizumab (Avastin) during postinduction chemotherapy-free intervals in metastatic colorectal cancer. Study Details In the open-label trial, 491 patients from ...

ASPIRE Trial: Final Overall Survival Results in Relapsed or Refractory Multiple Myeloma

The final overall survival results of the phase III ASPIRE trial indicate significant improvement with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) vs lenalidomide plus dexamethasone (Rd) in patients who had received one to three prior lines of therapy for multiple...

Obstetric and Neonatal Outcomes With Cancer Diagnosed During Pregnancy

As reported by de Haan et al in The Lancet Oncology, data from the International Network on Cancer, Infertility and Pregnancy (INCIP) registry indicate that use of chemotherapy during pregnancy has increased over a 20-year period, and that infants exposed to antenatal chemotherapy may be more...

Patients With Melanoma Treated With Anti–PD-1 Antibodies Beyond RECIST Progression

A pooled analysis by the U.S. Food and Drug Administration (FDA) has shown a benefit of treatment beyond progression, as defined by RECIST criteria, in many patients receiving anti–programmed cell death protein 1 (PD-1) antibodies for unresectable or metastatic melanoma. The analysis was ...

Racial Differences in Breast Cancer 21-Gene Recurrence Scores

In a study reported in the Journal of Clinical Oncology, Holowatyj et al found that among women with hormone receptor–positive, HER2-negative, node-negative invasive breast cancer, non-Hispanic black women had higher 21-gene recurrence scores  at diagnosis vs non-Hispanic white women....

Multiple-Basket Study of Targeted Therapy for Advanced Solid Tumors

In a phase IIa multiple-basket study (MyPathway) reported in the Journal of Clinical Oncology, Hainsworth et al found that agents targeting specific molecular alterations produced responses in tumors outside of current labeling for the agents, with high response rates being observed in some tumor...

Patient-Reported Outcomes With Addition of Combination Treatment to ADT in Newly Diagnosed Metastatic Castration-Naive Prostate Cancer

As reported by Chi et al in The Lancet Oncology, the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) in the phase III LATITUDE trial was associated with improved patient-reported outcomes in patients with newly diagnosed metastatic castration-naive prostate cancer. The...

Addition of Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery in Advanced Ovarian Cancer

In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by van Driel et al, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery following neoadjuvant chemotherapy was associated with significantly improved recurrence-free and...

Germline BRCA Mutation and Outcomes in Young-Onset Breast Cancer

In the POSH study in the UK population reported in The Lancet Oncology, Copson et al found women with young-onset breast cancer who carry a germline BRCA mutation have survival similar to noncarriers, and BRCA-mutation carriers vs noncarriers with triple-negative breast cancer may have an early...

Advertisement



Advertisement


Advertisement